RLY-2139 / Relay Therap - LARVOL DELTA

Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire) - "Paused near-term commercial readiness activities for CCA to align with the broader tumor agnostic opportunity being pursued....Announced plans to initiate RLY-2608 + fulvestrant + CDK4/6 triplet combinations in patients with PI3Kα-mutant, HR+, HER2- locally advanced or metastatic breast cancer by the end of 2023....Paused further development efforts on RLY-2139 (CDK2 inhibitor)....Anticipated Upcoming Milestones: (i) Lirafugratinib: report additional tumor agnostic clinical data and regulatory update in 2024; (ii) Pre-clinical: disclose new program(s) in 2024."

Clinical data • New trial • Pipeline update • Regulatory • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer

Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire) - "Recent Corporate Highlights:...(i) RLY-5836 (pan-mutant and isoform-selective PI3Kα inhibitor): In April 2023, initiated a first-in-human trial in patients with advanced solid tumors with a PIK3CA (PI3Kα) mutation; (ii) RLY-2139 (CDK2 inhibitor): Selected development candidate; anticipate early 2024 clinical start, pending regulatory authorization."

New molecule • New trial • Trial status • Breast Cancer • Oncology • Solid Tumor